Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Cidara Therapeutics, Inc. (CDTX)

1.16   -0.27 (-18.88%) 03-24 16:00
Open: 1.43 Pre. Close: 1.43
High: 1.42 Low: 1.1301
Volume: 8,049,661 Market Cap: 96(M)

Technical analysis

as of: 2023-03-24 4:24:45 PM
Stoxline posted a SELL today, upgraded from strong sell. Downward movement continues, but could change at any time.
Target: Six months: 2.02     One year: 2.45
Support: Support1: 1.13    Support2: 0.94
Resistance: Resistance1: 1.72    Resistance2: 2.09
Pivot: 1.64
Moving Average: MA(5): 1.64     MA(20): 1.64
MA(100): 1.07     MA(250): 0.81
MACD: MACD(12,26): 0     Signal(9): 0
Stochastic oscillator: %K(14,3): 29.4     %D(3): 52.6
RSI: RSI(14): 37
52-week: High: 2.09  Low: 0.4
Average Vol(K): 3-Month: 3,129 (K)  10-Days: 6,153 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ CDTX ] has closed below the lower bollinger band by 13.5%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 66.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.43 - 1.44 1.44 - 1.45
Low: 1.11 - 1.12 1.12 - 1.13
Close: 1.15 - 1.16 1.16 - 1.17

Company Description

Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.

Headline News

Thu, 23 Mar 2023
Cidara stock falls amid selloff in antifungal space (NASDAQ:CDTX) - Seeking Alpha

Thu, 23 Mar 2023
Cidara's Lower Than Expected Q4 Earnings Overshadows FDA Nod For Antifungal Treatment - Yahoo Life

Thu, 23 Mar 2023
Why Is Cidara Therapeutics (CDTX) Stock Down 12% Today? - InvestorPlace

Thu, 23 Mar 2023
Cidara Therapeutics (CDTX) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Life

Thu, 23 Mar 2023
Coinbase Global, Cidara Therapeutics among premarket losers' pack - Seeking Alpha

Thu, 23 Mar 2023
Cidara Therapeutics: Q4 Earnings Snapshot - Yahoo Finance

Financial Analysis

Price to Book Value: Underperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 83 (M)
Shares Float 55 (M)
% Held by Insiders 9.6 (%)
% Held by Institutions 33.6 (%)
Shares Short 3,100 (K)
Shares Short P.Month 1,750 (K)

Stock Financials

EPS -0.55
EPS Est Next Qtl -0.88
EPS Est This Year -3.61
EPS Est Next Year -3.29
Book Value (p.s.) 0.12
Profit Margin (%) -54.3
Operating Margin (%) -54.3
Return on Assets (ttm) -35.2
Return on Equity (ttm) -840.2
Qtrly Rev. Growth 475.7
Gross Profit (p.s.) -0.29
Sales Per Share 0.74
EBITDA (p.s.) -0.4
Qtrly Earnings Growth 0
Operating Cash Flow -22 (M)
Levered Free Cash Flow -12 (M)

Stock Valuations

PE Ratio -2.15
PEG Ratio -0.1
Price to Book value 8.92
Price to Sales 1.56
Price to Cash Flow -4.29

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.